Oral zinc supplementation does not improve oxidative stress or vascular function in patients with type 2 diabetes with normal zinc levels

Atherosclerosis

Volumn 219, Issue 1, 2011, Pages 231-239

  Seet, Raymond C S ^a   Lee, Chung Yung J ^a,b   Lim, Erle C H ^a   Quek, Amy M L ^a   Huang, Huiwen ^a   Huang, Shan Hong ^b   Looi, Woan Foon ^b   Long, Lee Hua ^b   Halliwell, Barry ^b  

^a Dept Medicine Endocrinol Diabet   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Oxidative damage; Type 2 diabetes; Vascular function; Zinc

Indexed keywords

ALLANTOIN; BIOLOGICAL MARKER; GLUCONATE ZINC; HYDROXYICOSATETRAENOIC ACID; ISOPROSTANE DERIVATIVE; PLACEBO;

ADULT; AORTA PRESSURE; ARTICLE; AUGMENTATION INDEX; BLOOD SAMPLING; BLOOD VESSEL; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; DIET SUPPLEMENTATION; HEMODYNAMIC PARAMETERS; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATION; OXIDATIVE STRESS; PILOT STUDY; PRIORITY JOURNAL; PULSE WAVE; SERUM; URINALYSIS; VASCULAR ENDOTHELIUM; ZINC BLOOD LEVEL;

AGED; ALLANTOIN; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; DIETARY SUPPLEMENTS; F2-ISOPROSTANES; HUMANS; MALE; MIDDLE AGED; OXIDATIVE STRESS; ZINC;

EID: 81155159707     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.07.097     Document Type: Article

References (60)

1. Davi G., Falco A., Patrono C. Lipid peroxidation in diabetes mellitus. Antioxid Redox Signal 2005, 7:256-268.
2. Bashan N., Kovsan J., Kachko I., Ovadia H., Rudich A. Positive and negative regulation of insulin signaling by reactive oxygen and nitrogen species. Physiol Rev 2009, 89:27-71.
3. American Diabetes Association Diagnosis and classification of diabetes mellitus. Diabetes Care 2010, 33(Suppl. 1):S62-S69.
4. Jansen J., Karges W., Rink L. Zinc and diabetes - clinical links and molecular mechanisms. J Nutr Biochem 2009, 20:399-417.
5. Cunningham J.J., Fu A., Mearkle P.L., Brown R.G. Hyperzincuria in individuals with insulin-dependent diabetes mellitus: concurrent zinc status and the effect of high-dose zinc supplementation. Metabolism 1994, 43:1558-1562.
6. Foster M., Samman S. Zinc and redox signaling: perturbations associated with cardiovascular disease and diabetes mellitus. Antioxid Redox Signal 2010, 13:1549-1573.
7. Simon S.F., Taylor C.G. Dietary zinc supplementation attenuates hyperglycemia in db/db mice. Exp Biol Med (Maywood) 2001, 226:43-51.
8. Jenner A., Ren M., Rajendran R., et al. Zinc supplementation inhibits lipid peroxidation and the development of atherosclerosis in rabbits fed a high cholesterol diet. Free Radic Biol Med 2007, 42:559-566.
9. Faure P., Benhamou P.Y., Perard A., Halimi S., Roussel A.M. Lipid peroxidation in insulin-dependent diabetic patients with early retina degenerative lesions: effects of an oral zinc supplementation. Eur J Clin Nutr 1995, 49:282-288.
10. Roussel A.M., Kerkeni A., Zouari N., Mahjoub S., Matheau J.M., Anderson R.A. Antioxidant effects of zinc supplementation in Tunisians with type 2 diabetes mellitus. J Am Coll Nutr 2003, 22:316-321.
11. Anderson R.A., Roussel A.M., Zouari N., Mahjoub S., Matheau J.M., Kerkeni A. Potential antioxidant effects of zinc and chromium supplementation in people with type 2 diabetes mellitus. J Am Coll Nutr 2001, 20:212-218.
12. Foster M., Petocz P., Samman S. Effects of zinc on plasma lipoprotein cholesterol concentrations in humans: a meta-analysis of randomised controlled trials. Atherosclerosis 2010, 210:344-352.
13. Beletate V., El Dib R.P., Atallah A.N. Zinc supplementation for the prevention of type 2 diabetes mellitus. Cochrane Database Syst Rev 2007, CD005525.
14. Andriollo-Sanchez M., Hininger-Favier I., Meunier N., et al. No antioxidant beneficial effect of zinc supplementation on oxidative stress markers and antioxidant defenses in middle-aged and elderly subjects: the Zenith study. J Am Coll Nutr 2008, 27:463-469.
15. Partida-Hernandez G., Arreola F., Fenton B., Cabeza M., Roman-Ramos R., Revilla-Monsalve M.C. Effect of zinc replacement on lipids and lipoproteins in type 2-diabetic patients. Biomed Pharmacother 2006, 60:161-168.
16. Knight J.A., Pieper R.K., McClellan L. Specificity of the thiobarbituric acid reaction: its use in studies of lipid peroxidation. Clin Chem 1988, 34:2433-2438.
17. Halliwell B., Gutteridge J. Free radicals in biology and medicine 2007, Oxford University Press, UK. fourth ed.
18. Yang Y.J., Choi B.Y., Chun B.Y., et al. Dietary zinc intake is inversely related to subclinical atherosclerosis measured by carotid intima-media thickness. Br J Nutr 2010, 104:1202-1211.
19. Bao B., Prasad A.S., Beck F.W., et al. Zinc supplementation decreases oxidative stress, incidence of infection, and generation of inflammatory cytokines in sickle cell disease patients. Transl Res 2008, 152:67-80.
20. Halliwell B., Lee C.Y. Using isoprostanes as biomarkers of oxidative stress: some rarely considered issues. Antioxid Redox Signal 2010, 13:145-156.
21. 2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci U S A 1990, 87:9383-9387.
22. 2-isoprostanes from esterified phospholipids is catalyzed by intracellular and plasma platelet-activating factor acetylhydrolases. J Biol Chem 2006, 281:4616-4623.
23. Vassalle C., Botto N., Andreassi M.G., Berti S., Biagini A. Evidence for enhanced 8-isoprostane plasma levels, as index of oxidative stress in vivo, in patients with coronary artery disease. Coron Artery Dis 2003, 14:213-218.
24. Seet R.C., Lee C.Y., Lim E.C., et al. Oxidative damage in Parkinson disease: measurement using accurate biomarkers. Free Radic Biol Med 2010, 48:560-566.
25. Seet R.C., Lee C.Y., Chan B.P., et al. Oxidative damage in ischemic stroke revealed using multiple biomarkers. Stroke 2011, 42:2326-2329.
26. Roberts L.J., Montine T.J., Markesbery W.R., et al. Formation of isoprostane-like compounds (neuroprostanes) in vivo from docosahexaenoic acid. J Biol Chem 1998, 273:13605-13612.
27. Markesbery W.R., Kryscio R.J., Lovell M.A., Morrow J.D. Lipid peroxidation is an early event in the brain in amnestic mild cognitive impairment. Ann Neurol 2005, 58:730-735.
28. 4-isoprostanes as specific marker of docosahexaenoic acid peroxidation in Alzheimer's disease. J Neurochem 1999, 72:734-740.
29. Granville D.J., Tashakkor B., Takeuchi C., et al. Reduction of ischemia and reperfusion-induced myocardial damage by cytochrome P450 inhibitors. Proc Natl Acad Sci U S A 2004, 101:1321-1326.
30. Wang M.H., Guan H., Nguyen X., Zand B.A., Nasjletti A., Laniado-Schwartzman M. Contribution of cytochrome P-450 4A1 and 4A2 to vascular 20-hydroxyeicosatetraenoic acid synthesis in rat kidneys. Am J Physiol 1999, 276:F246-F253.
31. Zou A.P., Muirhead E.E., Cowley A.W., et al. Role of changes in renal hemodynamics and P-450 metabolites of arachidonic acid in the reversal of one-kidney, one clip hypertension. J Hypertens 1995, 13:557-566.
32. Roman R.J., Renic M., Dunn K.M., Takeuchi K., Hacein-Bey L. Evidence that 20-HETE contributes to the development of acute and delayed cerebral vasospasm. Neurol Res 2006, 28:738-749.
33. Pidgeon G.P., Lysaght J., Krishnamoorthy S., et al. Lipoxygenase metabolism: roles in tumor progression and survival. Cancer Metastasis Rev 2007, 26:503-524.
34. Grootveld M., Halliwell B. Measurement of allantoin and uric acid in human body fluids. A potential index of free-radical reactions in vivo?. Biochem J 1987, 243:803-808.
35. Gruber J., Tang S.Y., Jenner A.M., et al. Allantoin in human plasma, serum, and nasal-lining fluids as a biomarker of oxidative stress: avoiding artifacts and establishing real in vivo concentrations. Antioxid Redox Signal 2009, 11:1767-1776.
36. Seet R.C., Lee C.Y., Loke W.M., et al. Biomarkers of oxidative damage in cigarette smokers: which biomarkers might reflect acute versus chronic oxidative stress?. Free Radic Biol Med 2011, 50:1787-1793.
37. Diczfalusy U. Analysis of cholesterol oxidation products in biological samples. J AOAC Int 2004, 87:467-473.
38. Seet R.C., Lee C.Y., Lim E.C., et al. Oxidative damage in dengue fever. Free Radic Biol Med 2009, 47:375-380.
39. Gupta R., Garg V.K., Mathur D.K., Goyal R.K. Oral zinc therapy in diabetic neuropathy. J Assoc Physicians India 1998, 46:939-942.
40. Niewoehner C.B., Allen J.I., Boosalis M., Levine A.S., Morley J.E. Role of zinc supplementation in type II diabetes mellitus. Am J Med 1986, 81:63-68.
41. Seet R.C., Lee C.Y., Lim E.C., et al. Markers of oxidative damage are not elevated in otherwise healthy individuals with the metabolic syndrome. Diabetes Care 2010, 33:1140-1142.
42. 2-isoprostanes, hydroxyeicosatetraenoic products, and oxysterols from a single plasma sample. Free Radic Biol Med 2008, 44:1314-1322.
43. 4-neuroprostanes) derived from docosahexaenoic acid in vivo in humans by a stable isotope dilution mass spectrometric assay. J Chromatogr B Analyt Technol Biomed Life Sci 2004, 799:95-102.
44. 2-isoprostanes by gas chromatography-mass spectrometry. Biochem Biophys Res Commun 2004, 320:696-702.
45. Arnaud J., Bellanger J., Bienvenu F., Chappuis P., Favier A. Recommended method for assaying serum zinc with flame atomic absorption. Ann Biol Clin 1986, 44:77-87.
46. Li Y., Staessen J.A., Li L.H., Huang Q.F., Lu L., Wang J.G. Reference values for the arterial pulse wave in Chinese. Am J Hypertens 2008, 21:668-673.
47. Tsikas D. Simultaneous derivatization and quantification of the nitric oxide metabolites nitrite and nitrate in biological fluids by gas chromatography/mass spectrometry. Anal Chem 2000, 72:4064-4072.
48. Niewoehner C.B. Metabolic effects of dietary versus parenteral fructose. J Am Coll Nutr 1986, 5:443-450.
49. Fosmire G.J. Zinc toxicity. Am J Clin Nutr 1990, 51:225-227.
50. Maret W., Sandstead H.H. Zinc requirements and the risks and benefits of zinc supplementation. J Trace Elem Med Biol 2006, 20:3-18.
51. Peretz A., Papadopoulos T., Willems D., et al. Zinc supplementation increases bone alkaline phosphatase in healthy men. J Trace Elem Med Biol 2001, 15:175-178.
52. Prasad A.S., Beck F.W., Bao B., et al. Zinc supplementation decreases incidence of infections in the elderly: effect of zinc on generation of cytokines and oxidative stress. Am J Clin Nutr 2007, 85:837-844.
53. Al-Maroof R.A., Al-Sharbatti S.S. Serum zinc levels in diabetic patients and effect of zinc supplementation on glycemic control of type 2 diabetics. Saudi Med J 2006, 27:344-350.
54. Parham M., Amini M., Aminorroaya A., Heidarian E. Effect of zinc supplementation on microalbuminuria in patients with type 2 diabetes: a double blind, randomized, placebo-controlled, cross-over trial. Rev Diabet Stud 2008, 5:102-109.
55. Haase H., Rink L. Functional significance of zinc-related signaling pathways in immune cells. Annu Rev Nutr 2009, 29:133-152.
56. Schwartz S.L., Fischer J.S., Kipnes M.S. Sugar-free zinc gluconate glycine lozenges (Cold-Eeze) do not adversely affect glucose control in patients with type 1 or type 2 diabetes mellitus. Am J Ther 2001, 8:247-252.
57. Zou M.H., Cohen R., Ullrich V. Peroxynitrite and vascular endothelial dysfunction in diabetes mellitus. Endothelium 2004, 11:89-97.
58. Abou-Seif M.A., Youssef A.A. Evaluation of some biochemical changes in diabetic patients. Clin Chim Acta 2004, 346:161-170.
59. Chausmer A.B. Zinc, insulin and diabetes. J Am Coll Nutr 1998, 17:109-115.
60. Rungby J. Zinc, zinc transporters and diabetes. Diabetologia 2010, 53:1549-1551.